$IOVA Profitability Lock + $AQST Anaphylm Pre-Approval Traction = Biotech-AI Earnings Operationalize Into 1H27 Execution

November 5, 2026

The Signal

$IOVA posted Q3 earnings (11/5) that flip the narrative from risk to execution: $122M revenue, 60% gross margin, $382M cash runway into 2029, and EPS improvement from -$0.25 (Q3 2025) to -$0.05 (Q3 2026). sBLA filing for biomarker-stratified NSCLC (KRAS WT cohort, 85.7% ORR + pembro frontline) locks a second regulatory pathway with higher efficacy density than broad-label attempt. Simultaneously, $AQST Q3 earnings (11/3 AH, 11/4 call) confirm Anaphylm NDA resubmission momentum—PharmFilm solves 30-year portability gap vs. EpiPen incumbency. Neither play requires AI hype. Both require manufacturing scale and payer adoption. Street has priced execution risk, not optionality into profitability.

IMPORTANT
Precision TIL cash runway to profitability + Anaphylm pre-PDUFA approval lock Q1–Q2 2027 catalysts; biotech-AI intersection operationalizes via biomarker stratification and manufacturing moat, not discovery acceleration.

What's Moving

  • $IOVA (NSCLC biomarker stratification + profitability glide) — Q3 beat ($122M rev, -$0.05 EPS, $382M cash) validates precision TIL manufacturing moat (150+ ATCs operationalized). sBLA filing for KRAS WT cohort + new LUN-202 cohort removes clinical binary; 85.7% ORR frontline durability justifies secondary registration. $20–25M floor into 2H27 sBLA; 7x melanoma TAM expansion unlocks higher ceiling. (via @biotechscanner)
  • $AQST (Anaphylm pre-PDUFA + $2B epinephrine TAM) — Q3 earnings confirm NDA resubmission integrated with FDA feedback (HF trial + PK trial results "better than expected"). PharmFilm delivery solves portability; launch hiring (Medical Liaisons, Regional Directors) operationalizing. Allergy KOL enthusiasm locked post-CRL. $473M cap vs. $1.8B post-approval floor = 3.8x upside into 1H27. (via @biotechscanner)
  • Manufacturing footprint as biotech-AI moat — $AQST's 50M+/year manufacturing business + $IOVA's 150+ ATC cell therapy capability demonstrate that biomarker-stratified oncology + precision delivery are capital-intensive, not AI-proof plays. Reduces commodity biotech risk; locks TAM defensibility.

Crosscurrents

  • $MDGL safety allegation noise vs. earnings reality — Whistleblower complaint (Charlton v. Madrigal, filed Oct 2026) alleges retaliation under Sarbanes-Oxley; company denies. Q3 revenue $431M (beat). @adamfeuerstein flagged; @biotech2k1 dismisses as "fearmongering" (55k+ patients on drug, 100% YoY growth). Safety risk is real if substantiated; margin risk if not. Stock reaction: modest. Execution > noise. (via @adamfeuerstein, @biotech2k1)
  • $RVMD Rasonque launch velocity vs. expectations cliff — $198M Q3 sales + 5k+ patients in first 5 weeks. @adamfeuerstein reports buyside now models $80–100M Q3 (if partial quarter paid), $400–500M Q4. Consensus was $26M. Stratospheric expectations embedded; payer adoption clarity critical into Q4. Risk reimbursement tightening post-launch euphoria.

Tradecraft

BULL
$IOVA: profitability line-of-sight (cash to 2029 + -$0.05 EPS) removes valuation ceiling; sBLA filing for biomarker cohort eliminates binary approval cliff into 2H27.
WATCH
$AQST PDUFA timing: Neffy approved in 142 days post-resubmission (March 2022 model); Anaphylm resubmission should accelerate vs. March 16, 2027 target. Any pre-holiday approval signal (Nov–Dec 2026) triggers 3–5x move.

Desk Notes

  • @biotechscanner — All-in on precision TIL + Anaphylm thesis; largest $IOVA holding, added significantly to $AQST; expects profitability Q1 2027 for Iovance.
  • @biotech2k1 — Fading biotech rally into year-end; selling into FOMO; rotating cash to tech parts suppliers (low debt, high margin). Sees data center capex headwind from blue-wave regulation, not biotech upside.
  • @adamfeuerstein — Tracking $RVMD launch traction + $MDGL safety allegations in real time; bullish on $RVMD commercial runway; skeptical of safety noise unless substantiated.

Get Biotech + AI Investors delivered — AI-synthesized from curated sources, daily.

🔔 Subscribe